MDxHealth VP granted stock options

MDxHealth SA reported that VP of Finance and Accounting Brendan O'Connell received two grants of share options.

Rhea-AI Filing Summary

MDxHealth SA reported that VP of Finance and Accounting Brendan O'Connell received two grants of share options. One grant covers 65,000 options to purchase ordinary shares at an exercise price of $0.76 per share, vesting based on Company performance criteria evaluated by the Board at the end of specified performance periods. A second grant covers 35,000 options at the same $0.76 exercise price, vesting in three equal annual installments on each of the first three anniversaries of the grant date. These awards increase his derivative-based compensation exposure without involving any open-market purchases or sales.

Insider Trade Summary

Grant/Award: 100,000 shares

Grant/Award 2 txns

Insider OConnell Brendan

Role VP, Finance and Accounting

Type	Security	Shares	Price	Value
Grant/Award	Share Option	35,000	$0.00	$0.00
Grant/Award	Share Option	65,000	$0.00	$0.00

Holdings After Transaction: Share Option — 100,000 contracts (Direct)

Footnotes (2)

1. F1. Represents options to purchase ordinary shares at a price per share of $0.76 granted on June 1, 2026. The options vest upon the achievement of certain Company performance criteria evaluated by the Board of Directors at the end of the relevant performance periods.
2. F2. Represents options to purchase ordinary shares at a price per share of $0.76 granted on June 1, 2026 . The options vest in three equal installments on each of the first three anniversaries of the date of grant.

Key Figures

Performance-based options grant: 65,000 options at $0.76 Time-based options grant: 35,000 options at $0.76 Total options after first grant: 65,000 options +2 more

5 metrics

Performance-based options grant 65,000 options at $0.76 Granted June 1, 2026; vest on Company performance criteria

Time-based options grant 35,000 options at $0.76 Granted June 1, 2026; vest over three anniversaries

Total options after first grant 65,000 options Total derivative holdings following first transaction entry

Total options after second grant 35,000 options Total derivative holdings following second transaction entry

Option expiration date June 27, 2035 Expiration for both option grants

Key Terms

Share Option, performance criteria, vest in three equal installments, ordinary shares

4 terms

Share Option financial

"Represents options to purchase ordinary shares at a price per share of $0.76 granted on June 1, 2026."

performance criteria financial

"The options vest upon the achievement of certain Company performance criteria evaluated by the Board of Directors."

vest in three equal installments financial

"The options vest in three equal installments on each of the first three anniversaries of the date of grant."

ordinary shares financial

"Represents options to purchase ordinary shares at a price per share of $0.76 granted on June 1, 2026."

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did MDxHealth (MDXH) report for Brendan O'Connell?

MDxHealth reported that VP of Finance and Accounting Brendan O'Connell received two grants of share options. The awards cover 65,000 and 35,000 options, providing the right to purchase ordinary shares at a fixed exercise price.

How many MDxHealth share options were granted to Brendan O'Connell?

Brendan O'Connell was granted 65,000 share options in one award and 35,000 share options in a second award. Each option relates to one ordinary share, increasing his equity-linked compensation position at MDxHealth through derivative securities rather than immediate share ownership.

What is the exercise price of Brendan O'Connell’s MDxHealth options?

Both option grants to Brendan O'Connell carry an exercise price of $0.76 per ordinary share. This means he can buy MDxHealth shares at $0.76 if and when the options vest and are exercised, regardless of the market price at that time.

How do Brendan O'Connell’s performance-based MDxHealth options vest?

The 65,000-share option grant vests upon achievement of specified Company performance criteria. These criteria are evaluated by MDxHealth’s Board of Directors at the end of the relevant performance periods, tying vesting to corporate results rather than solely to time in role.

What is the vesting schedule for Brendan O'Connell’s time-based MDxHealth options?

The 35,000-share option grant to Brendan O'Connell vests in three equal installments. Vesting occurs on each of the first three anniversaries of the June 1, 2026 grant date, creating a multi-year retention incentive tied to his continued service with MDxHealth.

When do Brendan O'Connell’s MDxHealth share options expire?

Both option grants are scheduled to expire on June 27, 2035. If the options are not exercised by that expiration date, they will lapse, and Brendan O'Connell will no longer have the right to purchase MDxHealth ordinary shares under these specific awards.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/03/2026 - 05:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

OConnell Brendan

(Last) (First) (Middle)

CAP BUSINESS CENTER

ZONE INDUSTRIELLE DES HAUTS-SARTS

(Street)

HERSTAL BELGIUM 4040

(City) (State) (Zip)

BELGIUM

(Country)

2. Issuer Name and Ticker or Trading Symbol
MDxHealth SA [ MDXH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	VP, Finance and Accounting

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option	$0.76	06/01/2026		A		35,000		(1)	06/27/2035	Ordinary Shares	35,000	$0	35,000	D
Share Option	$0.76	06/01/2026		A		65,000		(2)	06/27/2035	Ordinary Shares	65,000	$0	65,000	D

Explanation of Responses:

1. Represents options to purchase ordinary shares at a price per share of $0.76 granted on June 1, 2026. The options vest upon the achievement of certain Company performance criteria evaluated by the Board of Directors at the end of the relevant performance periods.

2. Represents options to purchase ordinary shares at a price per share of $0.76 granted on June 1, 2026 . The options vest in three equal installments on each of the first three anniversaries of the date of grant.

	/s/ Mark Busch, as attorney-in-fact for Brendan O'Connell	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)